Lonza Group AG (LZAGF)
OTCMKTS
· Delayed Price · Currency is USD
691.15
+26.15 (3.93%)
Apr 25, 2025, 3:53 PM EDT
Lonza Group AG Revenue
In the year 2024, Lonza Group AG had annual revenue of 6.57B CHF, down -2.13%. Lonza Group AG had revenue of 3.52B in the half year ending December 31, 2024, with 8.52% growth.
Revenue
6.57B CHF
Revenue Growth
-2.13%
P/S Ratio
6.74
Revenue / Employee
347.02K CHF
Employees
18,944
Market Cap
48.87B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6.57B | -143.00M | -2.13% |
Dec 31, 2023 | 6.72B | 494.00M | 7.94% |
Dec 31, 2022 | 6.22B | 814.00M | 15.05% |
Dec 31, 2021 | 5.41B | 901.00M | 19.99% |
Dec 31, 2020 | 4.51B | 301.00M | 7.15% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Lonza Group AG News
- 23 days ago - Lonza: Well Equipped In The U.S., Buy Confirmed - Seeking Alpha
- 2 months ago - Lonza Group Appears To Be Fully Valued At This Time (Rating Downgrade) - Seeking Alpha
- 3 months ago - Lonza Posts Lower Sales, Earnings But Expects Capsules Business Rebound This Year - The Wall Street Journal
- 6 months ago - Lonza Sees Accelerating Sales Growth in Final Quarter - The Wall Street Journal
- 7 months ago - Acumen Pharmaceuticals extends collaboration with Lonza - Seeking Alpha
- 7 months ago - Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease - Benzinga
- 9 months ago - Lonza Group AG (LZAGY) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Lonza Group AG (LZAGY) Q1 2024 Earnings Call Transcript - Seeking Alpha